X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Copay coupons can help ease patients’ out-of-pocket costs

By Holly Campbell  |    February 16, 2018
Each year, middlemen, like pharmacy benefit managers (PBMs) and insurers, shift more of the costs of health care to patients. Ensuring patients have affordable access to their medicines is the top...   Read More

PhRMA launches new consumer-facing Let’s Talk About Cost website

By Holly Campbell  |    January 24, 2018
Today, as part of the Let’s Talk About Cost campaign, PhRMA launched LetsTalkAboutCost.org, a national consumer-facing website to provide consumers with easy-to-understand information about the...   Read More

Video: What is a results-based contract?

By Katie Koziara  |    November 13, 2017
New medicines are revolutionizing how we fight disease, but too often patients have to fight to access innovative treatments. As part of the solution to this problem, biopharmaceutical companies...   Read More

How much are hospitals marking up the price of medicines? The answer may surprise you.

By Robert Zirkelbach  |    October 17, 2017
Hospitals mark up medicine prices, on average, nearly 500 percent, according to a new analysis from the Moran Company that was commissioned by the Pharmaceutical Research and Manufacturers of...   Read More

Foreign government price setting by any name harms innovation and access to medicines

By Kevin Haninger  |    June 6, 2017
In an effort to contain health care spending, some foreign governments mandate prices for innovative medicines at levels below the value they provide to patients, health care systems, and the...   Read More

Compulsory licensing: A misused and abused international trade law

By Jay Taylor  |    May 16, 2017
To maintain our position as the world’s top biopharmaceutical innovator, the U.S. biopharmaceutical industry needs predictable and reliable intellectual property protections. Compulsory licensing...   Read More

Government-imposed price controls threaten innovation and access

By Jay Taylor  |    May 9, 2017
It’s no coincidence that America leads the world in the discovery and development of new lifesaving medicines. U.S. biopharmaceutical innovators invest $60 billion in R&D annually – more than any...   Read More

Biopharmaceutical industry’s success reducing disparities for African Americans

By Myisha Gatson  |    February 16, 2017
February is Black History Month, and here at PhRMA, we continue our decades-long commitment to reducing disparities in health care for minorities through developing and helping communities access...   Read More

Medicare Monday: What is IPAB, and why is it bad for patients?

By Nicole Longo  |    February 13, 2017
In 2017, the Independent Payment Advisory Board (IPAB)couldfinally go into effect and come between patients and their health care providers. This week, we’re looking into this dangerous body.     Read More

4 things to think about when choosing your health plan

By Allyson Funk  |    October 28, 2016
Open enrollment is upon us once again. Whether you are picking a plan through your employer or a health insurance marketplace, whether you are getting coverage for the first time or changing to a...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates